ZA200905636B - Stable antibody formulations - Google Patents

Stable antibody formulations

Info

Publication number: ZA200905636B
Authority: ZA; South Africa
Prior art keywords: antibody formulations; stable antibody; stable; formulations; antibody
Prior art date: 2007-03-22

Application number

ZA200905636A

Other languages

English (en)

Inventor

Arvind Srivastava

Joel Goldstein

Original Assignee

Imclone Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-03-22

Filing date

2009-08-13

Publication date

2010-10-27

2009-08-13 Application filed by Imclone Llc filed Critical Imclone Llc

2010-10-27 Publication of ZA200905636B publication Critical patent/ZA200905636B/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Mycology (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Oil, Petroleum & Natural Gas (AREA)
Hematology (AREA)
Oncology (AREA)
Dermatology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

ZA200905636A 2007-03-22 2009-08-13 Stable antibody formulations ZA200905636B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US91974407P	2007-03-22	2007-03-22

Publications (1)

Publication Number	Publication Date
ZA200905636B true ZA200905636B (en)	2010-10-27

Family

ID=39766776

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200905636A ZA200905636B (en)	2007-03-22	2009-08-13	Stable antibody formulations

Country Status (18)

Country	Link
US (1)	US20100260766A1 (fr)
EP (1)	EP2136839A4 (fr)
JP (1)	JP2010522208A (fr)
KR (1)	KR20090113340A (fr)
CN (1)	CN101668540A (fr)
AU (1)	AU2008228823A1 (fr)
BR (1)	BRPI0809112A2 (fr)
CA (1)	CA2681743A1 (fr)
CR (1)	CR11005A (fr)
DO (1)	DOP2009000222A (fr)
EA (1)	EA200970880A1 (fr)
EC (1)	ECSP099642A (fr)
IL (1)	IL200321A0 (fr)
MX (1)	MX2009010179A (fr)
TN (1)	TN2009000382A1 (fr)
UA (1)	UA96473C2 (fr)
WO (1)	WO2008116103A2 (fr)
ZA (1)	ZA200905636B (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20160279239A1 (en)	2011-05-02	2016-09-29	Immunomedics, Inc.	Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US20160355591A1 (en)	2011-05-02	2016-12-08	Immunomedics, Inc.	Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
TW200838559A (en) *	2006-11-29	2008-10-01	Imclone Systems Inc	Insulin-like growth factor-1 receptor antagonists for modulation of weight and liposity
PE20090368A1 (es)	2007-06-19	2009-04-28	Boehringer Ingelheim Int	Anticuerpos anti-igf
CN102272154A (zh)	2008-10-29	2011-12-07	惠氏有限责任公司	单域抗原结合性分子的纯化方法
CA2738243C (fr)	2008-10-29	2020-09-29	Wyeth Llc	Formulations de molecules de liaison d'antigene monodomaines
BRPI0921845A2 (pt) *	2008-11-12	2019-09-17	Medimmune Llc	formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata
EP2196476A1 (fr) *	2008-12-10	2010-06-16	Novartis Ag	Formulation d'anticorps
MY150984A (en)	2008-12-12	2014-03-31	Boehringer Ingelheim Int	Anti-agf antibodies
TWI609698B (zh)	2010-01-20	2018-01-01	Chugai Pharmaceutical Co Ltd	穩定化的含抗體溶液製劑
WO2012028683A1 (fr)	2010-09-02	2012-03-08	Novartis Ag	Système de gel d'anticorps pour administration de médicament prolongée
TWI621625B (zh)	2010-09-17	2018-04-21	巴克斯歐塔公司	在弱酸性至中性ｐｈ中經由具有組胺酸的水性調配物穩定免疫球蛋白
HUE044038T2 (hu)	2010-11-05	2019-09-30	Novartis Ag	Spondilitisz ankilopoetika kezelési eljárásai anti-IL-17 alkalmazásával
JP6024025B2 (ja)	2011-05-02	2016-11-09	イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ，Ｉｎｃ．	少容量投与用のアロタイプ選択抗体の限外濾過濃縮
KR102091294B1 (ko) *	2011-10-26	2020-04-16	암젠 인크	Uv 광으로의 노출로 인한 단백질 변형 및 분해의 감소 또는 제거 방법
CN107880123A (zh)	2011-10-28	2018-04-06	普罗典娜生物科学有限公司	识别α‑突触核蛋白的人源化抗体
AU2013211874B2 (en)	2012-01-27	2017-11-02	Prothena Biosciences Limited	Humanized antibodies that recognize alpha-synuclein
AR092862A1 (es) *	2012-07-25	2015-05-06	Hanmi Pharm Ind Co Ltd	Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
AR094821A1 (es) *	2012-07-25	2015-09-02	Hanmi Pharm Ind Co Ltd	Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
AR091902A1 (es) *	2012-07-25	2015-03-11	Hanmi Pharm Ind Co Ltd	Formulacion liquida de un conjugado de insulina de accion prolongada
UA118441C2 (uk)	2012-10-08	2019-01-25	Протена Біосаєнсиз Лімітед	Антитіло, що розпізнає альфа-синуклеїн
JP2016505601A (ja)	2012-12-26	2016-02-25	ウォックハートリミテッド	医薬組成物
US20140255413A1 (en)	2013-03-07	2014-09-11	Boehringer Ingelheim International Gmbh	Combination therapy for neoplasia treatment
US9700485B2 (en)	2013-04-24	2017-07-11	Corning Incorporated	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
NL1040254C2 (en) *	2013-05-17	2014-11-24	Ablynx Nv	Stable formulations of immunoglobulin single variable domains and uses thereof.
US10513555B2 (en) *	2013-07-04	2019-12-24	Prothena Biosciences Limited	Antibody formulations and methods
US9603927B2 (en)	2014-02-28	2017-03-28	Janssen Biotech, Inc.	Combination therapies with anti-CD38 antibodies
US9732154B2 (en)	2014-02-28	2017-08-15	Janssen Biotech, Inc.	Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
CA2944402A1 (fr)	2014-04-08	2015-10-15	Prothena Biosciences Limited	Navettes de la barriere hemato-encephalique contenant des anticorps reconnaissant l'alpha-synucleine
KR102597989B1 (ko)	2014-12-04	2023-11-02	얀센 바이오테크 인코포레이티드	급성 골수성 백혈병을 치료하기 위한 항-cd38 항체
EP3256154B1 (fr) *	2015-02-09	2019-10-02	UCB Biopharma SPRL	Formulation pharmaceutique comprenant des anticorps
IL319936A (en)	2015-05-20	2025-05-01	Janssen Biotech Inc	Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies
AR104847A1 (es) *	2015-06-17	2017-08-16	Lilly Co Eli	Formulación de anticuerpo anti-cgrp
US20170044265A1 (en)	2015-06-24	2017-02-16	Janssen Biotech, Inc.	Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
EP4516319A3 (fr) *	2015-11-03	2025-05-07	Janssen Biotech, Inc.	Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations
JP6992262B2 (ja) *	2016-03-31	2022-02-15	東ソー株式会社	変性抗体測定試薬の製造方法
CN110352201A (zh)	2017-04-03	2019-10-18	免疫医疗公司	用于癌症疗法的抗体药物缀合物的皮下施用
MA50514A (fr)	2017-10-31	2020-09-09	Janssen Biotech Inc	Méthodes de traitement du myélome multiple à haut risque
CN120241997A (zh)	2019-02-18	2025-07-04	伊莱利利公司	治疗性抗体制剂
CN112206320B (zh) *	2019-07-12	2025-02-25	鲁南制药集团股份有限公司	一种cd47单克隆抗体冻干粉制剂及其制备工艺
CN113967195A (zh) *	2020-07-22	2022-01-25	三生国健药业（上海）股份有限公司	抗her2/pd1双特异性抗体冻干制剂及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0565233A (ja) *	1991-03-08	1993-03-19	Mitsui Toatsu Chem Inc	モノクローナル抗体含有凍結乾燥製剤
EP0940468A1 (fr) *	1991-06-14	1999-09-08	Genentech, Inc.	Domaine variable d'un anticorps humanisé
US6267958B1 (en) *	1995-07-27	2001-07-31	Genentech, Inc.	Protein formulation
IL155002A0 (en) *	2000-10-12	2003-10-31	Genentech Inc	Reduced-viscosity concentrated protein formulations
DK2270052T3 (en) *	2001-06-26	2018-07-02	Amgen Inc	Antibodies to OPGL
CA2454587C (fr) *	2001-07-25	2012-11-13	Protein Design Labs, Inc.	Formulation pharmaceutique lyophilisee stable d'anticorps igg
MXPA04007924A (es) *	2002-02-14	2005-05-17	Chugai Pharmaceutical Co Ltd	Formulaciones en solucion que contienen anticuerpo.
PL378812A1 (pl) *	2003-02-13	2006-05-29	Pfizer Products Inc.	Zastosowania przeciwciał przeciw receptorowi insulinopodobnego czynnika wzrostowego I
EP2365001A3 (fr) *	2003-05-01	2012-03-28	Imclone LLC	Anticorps humains dirigés contre le récepteur de facteur 1 de croissance de type insuline humaine
US7579157B2 (en) *	2003-07-10	2009-08-25	Hoffmann-La Roche Inc.	Antibody selection method against IGF-IR
ES2351395T3 (es) *	2003-08-13	2011-02-04	Pfizer Products Inc.	Anticuerpos humanos modificados anti-igf-1r.
AU2006247039B2 (en) *	2005-05-19	2011-03-03	Amgen Inc.	Compositions and methods for increasing the stability of antibodies
KR20080019249A (ko) *	2005-06-15	2008-03-03	쉐링 코포레이션	안정한 항체 제형
AU2007229554A1 (en) *	2006-03-28	2007-10-04	F. Hoffmann-La Roche Ag	Anti-IGF-1R human monoclonal antibody formulation

2008
- 2008-03-20 MX MX2009010179A patent/MX2009010179A/es not_active Application Discontinuation
- 2008-03-20 UA UAA200909552A patent/UA96473C2/ru unknown
- 2008-03-20 US US12/528,882 patent/US20100260766A1/en not_active Abandoned
- 2008-03-20 JP JP2009554753A patent/JP2010522208A/ja active Pending
- 2008-03-20 EA EA200970880A patent/EA200970880A1/ru unknown
- 2008-03-20 WO PCT/US2008/057718 patent/WO2008116103A2/fr not_active Ceased
- 2008-03-20 CN CN200880009446A patent/CN101668540A/zh active Pending
- 2008-03-20 CA CA002681743A patent/CA2681743A1/fr not_active Abandoned
- 2008-03-20 BR BRPI0809112-9A patent/BRPI0809112A2/pt not_active IP Right Cessation
- 2008-03-20 KR KR1020097019642A patent/KR20090113340A/ko not_active Abandoned
- 2008-03-20 AU AU2008228823A patent/AU2008228823A1/en not_active Abandoned
- 2008-03-20 EP EP08744136A patent/EP2136839A4/fr not_active Withdrawn
2009
- 2009-08-10 IL IL200321A patent/IL200321A0/en unknown
- 2009-08-13 ZA ZA200905636A patent/ZA200905636B/xx unknown
- 2009-08-28 CR CR11005A patent/CR11005A/es not_active Application Discontinuation
- 2009-09-18 DO DO2009000222A patent/DOP2009000222A/es unknown
- 2009-09-18 TN TNP2009000382A patent/TN2009000382A1/fr unknown
- 2009-09-21 EC EC2009009642A patent/ECSP099642A/es unknown

Also Published As

Publication number	Publication date
AU2008228823A1 (en)	2008-09-25
EA200970880A1 (ru)	2010-02-26
CN101668540A (zh)	2010-03-10
WO2008116103A3 (fr)	2009-01-08
TN2009000382A1 (en)	2010-12-31
US20100260766A1 (en)	2010-10-14
CA2681743A1 (fr)	2008-09-25
WO2008116103A2 (fr)	2008-09-25
MX2009010179A (es)	2010-03-15
EP2136839A2 (fr)	2009-12-30
KR20090113340A (ko)	2009-10-29
EP2136839A4 (fr)	2010-04-07
IL200321A0 (en)	2010-04-29
DOP2009000222A (es)	2009-12-15
CR11005A (es)	2010-08-05
BRPI0809112A2 (pt)	2014-08-26
UA96473C2 (ru)	2011-11-10
ECSP099642A (es)	2009-11-30
JP2010522208A (ja)	2010-07-01

Publication	Publication Date	Title
IL200321A0 (en)	2010-04-29	Stable antibody formulations
IL202648A0 (en)	2011-08-01	Antibody formulations
ZA200909107B (en)	2012-12-27	Antibody formulations
EP2173163A4 (fr)	2010-12-08	Formulations d'anticorps
EP2077859A4 (fr)	2010-11-24	Formulation d'anticorps
IL206103A0 (en)	2010-11-30	Antibody formulation
SG10201604258YA (en)	2016-07-28	Anti-tnf antibody formulations
GB0711656D0 (en)	2007-07-25	Formulations
EP2046930A4 (fr)	2012-06-27	Formulations à base de rhamnolipides
GB0716385D0 (en)	2007-10-03	Formulations
GB0712884D0 (en)	2007-08-15	Formulations
GB0718409D0 (en)	2007-10-31	Formulations
GB0605780D0 (en)	2006-05-03	Formulations
GB0809979D0 (en)	2008-07-09	Formulations
GB0711957D0 (en)	2007-08-01	Formulations
GB0810232D0 (en)	2008-07-09	Formulations
GB0610336D0 (en)	2006-07-05	Formulations
EP2167635A4 (fr)	2010-06-30	Formulations d'anticorps
GB0705179D0 (en)	2007-04-25	Formulations
HK1134440A (en)	2010-04-30	Stable antibody formulations
GB0710900D0 (en)	2007-07-18	Formulations
GB0710346D0 (en)	2007-07-11	Formulations
GB0701993D0 (en)	2007-03-14	Formulations
GB0710350D0 (en)	2007-07-11	Formulations
GB0713886D0 (en)	2007-08-29	Formulations